Antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from a Malaysian Hospital

Malaysian Journal of Medical Sciences

Volumn 16, Issue 2, 2009, Pages 28-33

  Pathmanathan, Siva Gowri ^a   Samat, Nor Azura ^b   Mohamed, Ramelah ^c  

^a UNIVERSITI SAINS ISLAM MALAYSIA   (Malaysia)

^b HOSPITAL KUALA LUMPUR   (Malaysia)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Antibacterial agents; Bacterial drug resistance; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; EPSILOMETER TEST; IN VITRO STUDY; MALAYSIA; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 73149105313     PISSN: 1394195X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kiska DL, Gilligan PH. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen, JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology. 8th ed. Washington, DC: American Society for Microbiology, 200. p. 719728.
2. Pagani L, Montengoli E, Migliavacca R, Nucleo E, Pollini S, Spalla M, et al. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 Extended Spectrum â-lactamase in Northern Italy. J Clin Microbiol. 2004;42:25232529.
3. Ling TKW, Xiong J, Yu Y, Lee CC, Ye H, Hawkey PM. The MK0826 China Study Group. Multicenter Antimicrobial Susceptibility Survey of Gram Negative Bacteria Isolated from Patients with Community-Acquired Infections in the People's Republic of China. Antimicrob Agents Chemother. 2006;50:374378.
4. Gupta V, Datta P, Agnihotri N, Chander J. Comparative in vitro Activities of Seven New beta-Lactams, Alone and in Combination with beta-Lactamase Inhibitors, Against Clinical Isolates Resistant to Third Generation Cephalosporins. Braz J Infect Dis. 2006;10:2225.
5. Babay HAH. Antimicrobial Resistance among Clinical Isolates of Pseudomonas aeruginosa from Patients in a Teaching Hospital, Riyadh, Saudi Arabia, 20012005. Jpn J Infect Dis. 2007;60:123125.
6. Patzer JA, Dzierzanowska D. Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish paediatric hospital (19932002). Int J Antimicrob Agents. 2007;29:153158.
7. Walkty A, DeCorby M, Nichol K., Mulvey MR, Hoban D, Zhanel G. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. Diagn Microbiol Infect Dis. 2008;61:217221.
8. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 19971999. Clin Infect Dis. 2001;32:S146155.
9. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. 2003; 47:16811688.
10. Raja NS, Singh NN. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. J Microbiol Immunol Infect. 2007;40:4549.
11. Biedenbach DJ, Lewis MT, Jones RN. In vitro evaluation of cefepime and other broad-spectrum â-lactams for isolates in Malaysia and Singapore medical centers. Diagn Microbiol Infect Dis. 1999;35:277283.
12. Clinical and Laboratory Standards Institute. 2006 M100-S16. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute; 2006.
13. Luber P, Bartelt E, Genschow E, Wagner J, Hahn H. Comparison of Broth Microdilution, E Test, and Agar Dilution Methods for Antibiotic Susceptibility Testing of Campylobacter jejuni and Campylobacter coli. J Clin Microbiol. 2003; 41:10621068.
14. Rodríguez-Morales A, Rodríguez C, Garcia A, Pastran B, Jiménez I, Meijomil P. Antimicrobial resistance of Pseudomonas aeruginosa in pediatric infections. Int J Infect Dis. 2005;11:8485.
15. Yetkin G, Otlu B, Cicek A, Kuzucu C, Durmaz R. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey. Am J Infect Control. 2006;34:188192.
16. Taneja N, Maharwal S, Sharma M. Imipenem resistance in non-fermenters causing nosocomial urinary tract infections. Indian J Med Sci. 2003;57:294299.
17. Mendes C, Oplustil C, Sakagami E, Turner P, Kiffer C, MYSTIC Brazil Group. Antimicrobial susceptibility in intensive care units: MYSTIC Program Brazil. Braz J Infect Dis. 2002;9:4451.
18. Tam VH, Gamez EA, Weston JS, Gerard LN, LaRocco MT, Caeiro JP, et al. Outcomes of Bacteremia due to Pseudomonas aeruginosa with Reduced Susceptibility to Piperacillin-Tazobactam: Implications on the Appropriateness of the Resistance Breakpoint. Clin Infect Dis. 2008;46:862867.
19. Joyce LF, Downes J, Stockman K, Andrew JH. Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J Clin Microbiol. 1992;30: 27092713.
20. Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 2007;38:18181822.
21. Al-Tawfiq JA. Occurrence and antimicrobial resistance pattern of inpatient and outpatient isolates of Pseudomonas aeruginosa in a Saudi Arabian hospital: 19982003. Int J Infect Dis. 2007;11:109114.